EAM
PACB icon

Exome Asset Management’s Pacific Biosciences PACB Stock Holding History

Exome Asset Management’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-75,300
Closed -$128K – 74
2024
Q3 		$128K Hold
75,300
– – 0.09% 59
2024
Q2 		$103K Hold
75,300
– – 0.09% 52
2024
Q1 		$282K Hold
75,300
– – 0.24% 52
2023
Q4 		$739K Buy
+75,300
New +$616K 0.73% 42

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Exome Asset Management's PACB Position: Q4 2024 in Review

Exome Asset Management sold out of Pacific Biosciences (PACB) in Q4 2024, closing a stake of 75,300 shares — an estimated $128K sold.

Exome Asset Management first reported a position in PACB in Q4 2023 and held it in 4 quarters. The position peaked at $739K in Q4 2023. 226 funds tracked by Wall St. Rank hold PACB as of Q4 2024.

  • Exome Asset Management reported no remaining Pacific Biosciences position as of Q4 2024 after selling out during the quarter.
  • Exome Asset Management sold 75,300 Pacific Biosciences shares in Q4 2024, an estimated $128K.
  • Exome Asset Management first reported a position in Pacific Biosciences in Q4 2023 and held it in 4 quarters.
  • Exome Asset Management's Pacific Biosciences position peaked at $739K in Q4 2023.
  • 226 funds tracked by Wall St. Rank held Pacific Biosciences as of Q4 2024.

Based on Exome Asset Management's 13F filing for Q4 2024, filed 14 Feb 2025.